Preparation of cd73 positive nk cells from different starting sources of umbilical cord blood and application in treatment of alzheimer's disease

By differentiating CD73+ NK cells from umbilical cord blood, the imbalance between inflammation and oxidative stress in Alzheimer's disease (AD) was addressed, achieving the inhibition of neuroinflammation in the hippocampus and the regulation of oxidative stress response, thus providing an effective treatment option for AD.

CN121015869BActive Publication Date: 2026-03-17SHENZHEN ZHONGJIA BIOMEDICAL TECH CO LTD
1 Cites 0 Cited by

Patent Information

Application Number
CN202511543638.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-10-28
Publication Date
2026-03-17
Estimated Expiration
2045-10-28

AI Technical Summary

Technical Problem

Existing technologies are ineffective in treating Alzheimer's disease (AD) by addressing the imbalance between inflammatory response and oxidative stress, which leads to accelerated disease progression. Traditional immune cell therapies, such as CAR-T cells, have limitations, and NK cells, as a potential alternative, have not yet been fully developed for their anti-inflammatory and oxidative stress regulation functions.

Method used

CD73+ NK cells were differentiated from umbilical cord blood from different sources. By inhibiting the proliferation and differentiation of pro-inflammatory cells, the immune regulation capacity was enhanced, the level of inflammation-related cytokines was reduced, and oxidative stress was resisted through paracrine mechanisms. CD73+ NK cells were used to inhibit the activation of glial cells in the hippocampus and reduce neuroinflammation.

Benefits of technology

CD73+ NK cells can effectively inhibit the activation of microglia and astrocytes in the hippocampus, reduce inflammatory factors and oxidative stress, provide a new clinical treatment option for AD, and show higher growth rate and stronger cytotoxicity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention belongs to the field of medical technology, specifically relating to the preparation of CD73-positive NK cells from umbilical cord blood of different origins and their application in the treatment of Alzheimer's disease. This invention studies CD73-positive NK cells differentiated from different cell types originating from umbilical cord blood (CD34-positive cells, CD3-negative / CD56-positive cells, and CD56-negative cells). + NK cells were found to differentiate into CD73 from all initial cell types derived from umbilical cord blood. + NK cells, and 34 + -73-NK cells showed a higher growth rate, 56 － -73-NK cells exhibited stronger cytotoxicity, and 56 － -73-NK cells showed better overall efficacy than 34- + -73-NK cells. Further research indicates that CD73 + NK cells can inhibit the activation of microglia and astrocytes in the hippocampus of STZ-injected mice, thereby reducing neuroinflammation in the hippocampus and potentially providing a new solution for the treatment of AD.
Need to check novelty before this filing date? Find Prior Art